Evidence map›Paper›PMID 32023310›Full record

ArticlePloS one2020

Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection.

M Elle Saine, Tyler M Moore, Julia E Szymczak, Laura P Bamford, Frances K Barg, Nandita Mitra, Jason Schnittker, John H Holmes, Vincent Lo Re

Open access · goldAbstract readValidation Study
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Social challenges experienced by Hepatitis B patients: A mixed method study.Journal of family medicine and primary care · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

M Elle SaineCenter for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.ORCID 0000-0002-1037-5610
Tyler M MooreDepartment of Psychiatry, Brain Behavior Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
Julia E SzymczakCenter for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.ORCID 0000-0002-3230-8670
Laura P BamfordDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
Frances K BargCenter for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
Nandita MitraCenter for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
Jason SchnittkerLeonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, United States of America.
John H HolmesCenter for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
Vincent Lo ReCenter for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
University of Pennsylvania · USCommunity Health Center · US

Funding

Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV TherapyR01AI136626 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LO RE, VINCENT · 2018 to 2022
$4.0M
Training in Healthcare Financing, Organization and Delivery for Aging PopulationsT32AG051090 · NIA · UNIVERSITY OF PENNSYLVANIA · PI PAULY, MARK, WERNER, RACHEL M · 2015 to 2019
$652k
NIAID NIH HHS R01 AI136626NIA NIH HHS T32 AG051090
6 · The paper itself

Abstract

backgroundStigma around hepatitis C virus (HCV) infection is an important and understudied barrier to HCV prevention, treatment, and elimination. To date, no validated instrument exists to measure patients' experiences of HCV stigma. This study aimed to revise the Berger (2001) HIV stigma scale and evaluate its psychometric properties among patients with HCV infection.

methodsThe Berger HIV stigma scale was revised to ask about HCV and administered to patients with HCV (n = 270) in Philadelphia, Pennsylvania. Scale reliability was evaluated as internal consistency by calculating Cronbach's alpha. Exploratory factor analysis was performed to evaluate construct validity by comparing item clustering to the Berger HIV stigma scale subscales. Item response theory was employed to further evaluate individual items and to calibrate items for simulated computer adaptive testing sessions in order to identify potential shortened instruments.

resultsThe revised HCV Stigma Scale was found to have good reliability (α = 0.957). After excluding items for low loadings, the exploratory factor analysis indicated good construct validity with 85% of items loading on pre-defined factors. Analyses strongly suggested the predominance of an underlying unidimensional factor solution, which yielded a 33-item scale after items were removed for low loading and differential item functioning. Adaptive simulations indicated that the scale could be substantially shortened without detectable information loss.

conclusionsThe 33-item HCV Stigma Scale showed sufficient reliability and construct validity. We also conducted computer adaptive testing simulations and identified shortened six- and three-item scale alternatives that performed comparably to the original 40-item scale.

Indexed as

Health Knowledge, Attitudes, PracticePsychometricsSocial StigmaAdolescentAdultCross-Sectional StudiesFactor Analysis, StatisticalFemaleHepacivirusHepatitis CHIV InfectionsHumansMaleMiddle AgedPhiladelphiaReproducibility of Results

Identifiers

PMID32023310
PMCPMC7001940
OpenAlexW3005098435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.